These results suggest that, by strengthening immune surveillance, prophylactic immunotherapy with MUC1 substrates may be a strategy to reduce the risk of breast/ovarian cancer in BRCA1/2 mutation carriers [80]. The gene discussed is MUC1; the disease is ovarian carcinoma.